The Roles of Circular RNAs in Osteosarcoma

Zhang, Yong; Li, Jiale; Wang, Yinsheng; Jing, Juehua; Li, Jun

doi:10.12659/msm.915559

Cited by 37 publications

(30 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many circRNAs have involved into the pathogenesis of OS and became an important diagnostic and prognostic indicator in OS [16]. In the present study, overexpression of circ_0005909 was observed in both OS tissues and cell lines, which is consistent with previous studies [17,18].…”

Section: Discussionsupporting

confidence: 93%

Hsa_circ_0005909 promotes cell proliferation of osteosarcoma cells by targeting miR-338-3p/HMGA1 axis

Zhang

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Objective: Osteosarcoma (OS) is the most common malignant bone tumor in pediatric population. The main goal of this study is to investigate the role of has_circ_0005909 and the underlying signaling pathway involved in OS.Methods: Cell proliferation was measured using CCK-8 assay kit and clone formation assay. Change of RNA and protein expression was determined using RNA extract and quantitative real time PCR (RT-qPCR) assay and Western blotting, respectively. CircInteractome was used to predict the target of circRNA and starBase v2.0 was used to predict the target of miRNAs. Luciferase assay was used to confirm the predicted results from CircInteractome and starBase v2.0.Results: Expression of circ_0005909 was upregulated in both OS tissues and cell lines. The predicted results from CircInteractome and starBase v2.0 demonstrated that circ_0005909 could sponge miR-338-3p and that HGMA1 was the direct target of miR-338-3p. Cell viability and cell clones was inhibited by knockdown of circ_0005909 but increased by dual inhibition of circ_0005909 and miR-338-3p. Phosphorylation of ERK, Akt, PI3K was inhibited by sh-circ_0005909 while this inhibition was repressed by co-transfection of sh-circ_0005909 and HGMA1.Conclusion: Expression of circ_0005909 was upregulated in both OS tissues and cell lines which upregulated expression of HGMA1 through sponging miR-338-3p, resulting in the activation of MAPK-ERK and PI3K-Akt signaling pathways to promote the development of OS.

show abstract

Section: Discussionsupporting

confidence: 93%

Hsa_circ_0005909 promotes cell proliferation of osteosarcoma cells by targeting miR-338-3p/HMGA1 axis

Zhang

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…However, for its early diagnosis and treatment of early lung metastasis, we still need a faster and more advanced non-invasive examination method to increase patient survival rate and improve prognosis. The latest research of miRNAs showed that it has strong specificity in the occurrence and metastasis of malignant tumors [57] , [58] , and has become a new hot spot for many scholars to study early diagnosis and monitor tumors. Several literatures showed that miRNAs in peripheral blood showed a high diagnostic accuracy in distinguishing OS patients from healthy people, but the results were inconsistent.…”

Section: Discussionmentioning

confidence: 99%

Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: A meta-analysis

Gao

Wang²,

Zhang

et al. 2020

Journal of Bone Oncology

View full text Add to dashboard Cite

show abstract

“…Among non-coding elements, those that have been most extensively studied in HGOS are microRNAs (miRNAs) and long non-coding RNAs (lncRNAs). Although some evidence of the possible involvement of non-coding RNAs in HGOS pathogenesis has been reported [ 132 , 133 , 134 , 135 ], very few data have been provided so far regarding the potential impact of polymorphisms affecting miRNAs or lncRNAs on HGOS survival.…”

Section: Polymorphisms Of Non-coding Rnasmentioning

confidence: 99%

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Hattinger

Patrizio

Luppi

et al. 2020

IJMS

View full text Add to dashboard Cite

High-grade osteosarcoma (HGOS) is a very aggressive bone tumor which primarily affects adolescents and young adults. Although not advanced as is the case for other cancers, pharmacogenetic and pharmacogenomic studies applied to HGOS have been providing hope for an improved understanding of the biology and the identification of genetic biomarkers, which may impact on clinical care management. Recent developments of pharmacogenetics and pharmacogenomics in HGOS are expected to: i) highlight genetic events that trigger oncogenesis or which may act as drivers of disease; ii) validate research models that best predict clinical behavior; and iii) indicate genetic biomarkers associated with clinical outcome (in terms of treatment response, survival probability and susceptibility to chemotherapy-related toxicities). The generated body of information may be translated to clinical settings, in order to improve both effectiveness and safety of conventional chemotherapy trials as well as to indicate new tailored treatment strategies. Here, we review and summarize the current scientific evidence for each of the aforementioned issues in view of possible clinical applications.

show abstract

The Roles of Circular RNAs in Osteosarcoma

Cited by 37 publications

References 36 publications

Hsa_circ_0005909 promotes cell proliferation of osteosarcoma cells by targeting miR-338-3p/HMGA1 axis

Hsa_circ_0005909 promotes cell proliferation of osteosarcoma cells by targeting miR-338-3p/HMGA1 axis

Potential diagnostic value of miRNAs in peripheral blood for osteosarcoma: A meta-analysis

Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact

Contact Info

Product

Resources

About